Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Eur J Pharm Sci. 2019 Aug 5;138:105032. doi: 10.1016/j.ejps.2019.105032

Figure 2.

Figure 2.

The systems PK/PD model simulations of total antibody and free sTFPI in humans after IV and SC administration of concizumab. The dotted horizontal lines are the reported lower limit of quantification (LLOQ) for concizumab (Agerso et al., 2014) and sTFPI (Duckers et al., 2008).